SLC38A2を阻害すると,高血圧のネズミのモデルで血圧が低下する
Chunxiu Du1,2, Hu Xu2, Wenqian Zhao2
1Wuhu Hospital, East China Normal University, Wuhu, Anhui, 241000, China.
Science translational medicine
|September 3, 2025
まとめ
科学者はSLC38A2トランスポーターを ターゲットにすることで 血圧を低下させることが発見しました SLC38A2を阻害すると,酸化窒素 (NO) の生成が増加し,高血圧の新たな治療法となる可能性があります.
科学分野:
- 心血管研究
- 分子生物学
- 遺伝学
背景:
- 高血圧は 治療法が不十分で 世界的な健康問題です
- 血圧調節におけるナトリウム依存中性アミノ酸トランスポーターのSLC38A2の役割は不明である.
研究 の 目的:
- 血圧制御におけるSLC38A2の役割を調査する.
- 高血圧の潜在的治療標的としてSLC38A2を調査する.
主な方法:
- 全球および内皮細胞特異性Slc38a2ノックアウトマウスを生成した.
- 内皮細胞を分析するために単細胞RNA配列を解析した.
- 高血圧モデルにSLC38A2阻害剤メチラミノイオバートリック酸 (MeAIB) を投与した.
- 人口コホート (中国と英国のバイオバンク) の遺伝子変異を分析した.
主要な成果:
- Slc38a2 ノックアウトマウスは血圧の低下と窒素酸化物 (NO) バイオシンセシスの強化を示した.
- MeAIB治療は様々な高血圧マウスとラットモデルで血圧を下げました.
- SLC38A2 rs1873793の変異は,ヒト集団における高血圧リスクの増加と関連していました.
結論:
- SLC38A2は,内皮の酸化窒素 (NO) 信号を調節することによって血圧を調節する.
- SLC38A2を阻害すると,AKT- eNOS経路を通じてNOの生成が増加します.
- SLC38A2を標的とした治療は高血圧治療の有望な戦略です.
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
911
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911
01:25Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
751
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
751
01:16Antihypertensive Drugs: Action of Diuretics
870
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
870
01:23Antihypertensive Drugs: Vasodilators
642
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
642